The recommendation is to use additional contraceptive methods (or switch to non-oral contraception) during GLP-1 therapy, especially during dose changes
Do not do this without laboratory confirmation
This makes them inherently risky which is why the FDA only permits compounding in special situations, such as drug shortages
Patient Representative Office 212-639-7202 Call if you have questions about the Health Care Proxy form or concerns about your care
Upregulating Myc, SOX2, OCT4, and KLF4 in cardiomyocytes prior to and during MI can promote the dedifferentiation of mature cardiomyocytes, thereby reactivating the cell cycle and enhancing myocardial regeneration
Microdosing can also involve doing injections less frequently than prescribed, often biweekly or monthly instead of weekly